News from envisia therapeutics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 05, 2017, 08:15 ET Envisia Therapeutics To Present New Data At ARVO 2017 Annual Meeting

Envisia Therapeutics today announced that the Company will present new data for its next generation product candidate, ENV515 for glaucoma, as well...

May 03, 2017, 12:51 ET Envisia Therapeutics To Present New Data On Lead Programs At ASCRS 2017 Annual Meeting

Envisia Therapeutics today announced that the Company will present new data for its next generation product candidates, ENV515 for glaucoma and...

Mar 02, 2017, 15:27 ET Envisia Therapeutics To Present At American Glaucoma Society 2017 Annual Meeting

Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today...

Feb 03, 2017, 07:45 ET Envisia Therapeutics Releases Interim ENV515 (Travoprost XR) Phase 2 Data Demonstrating 11-Month Duration-of-Action After a Single Dose in Patients With Glaucoma

Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today...

Jan 04, 2017, 04:00 ET Envisia Therapeutics Announces Company President, Dr. Ben Yerxa, Will Present at the 35th J.P. Morgan Healthcare Conference

Envisia Therapeutics today announced that Company President, Dr. Benjamin Yerxa, has been invited to present at the 35th Annual J.P. Morgan...

Oct 17, 2016, 08:15 ET Envisia Therapeutics Releases ENV515 (travoprost XR) Phase 2 Data Showing Nine-Month Duration Of Action After A Single Dose In Patients With Glaucoma

Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today...

Oct 15, 2016, 12:33 ET Envisia Therapeutics To Present At AAO 2016 Annual Meeting

Envisia Therapeutics today announced that Dr. Thomas R. Walters, MD will present breakthrough clinical data for Envisia's ENV515 (travoprost XR)...

Oct 10, 2016, 11:20 ET Envisia Therapeutics Selected To Present During Anterior Segment Company Showcase At 2016 Ophthalmalogy Innovation Summit

Envisia Therapeutics today announced that it has been selected to present during the Anterior Segment Company Showcase at the 2016 Ophthalmology...

Sep 01, 2016, 10:28 ET Envisia Therapeutics Announces Panel Presentation At Upcoming Citi's 11th Annual Biotech Conference

Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology,...

Aug 10, 2016, 12:19 ET Envisia Therapeutics Announces Upcoming Presentation at Wedbush PacGrow Healthcare Conference

Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology,...

Jul 27, 2016, 06:00 ET Envisia Therapeutics Announces Presentation At 2016 Ophthalmic Drug Development Summit

Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology,...

May 03, 2016, 07:45 ET Envisia Therapeutics Announces Positive Three-Month Interim Results of Low Dose ENV515 in Patients with Glaucoma

Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today...

May 01, 2016, 11:16 ET Envisia Therapeutics To Present At ARVO 2016 Annual Meeting

Envisia Therapeutics today announced that eight posters have been selected for presentation at the Association for Research in Vision and...

Mar 23, 2016, 08:30 ET Envisia Therapeutics Secures $16.5 Million In Additional Series A Financing

Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today...

Jan 12, 2016, 08:15 ET Envisia Therapeutics Announces First Patient Dosed in Second Cohort of Novel Phase 2 Program Evaluating ENV515 in Patients with Glaucoma

Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today...

Jan 05, 2016, 07:30 ET Envisia Therapeutics Announces Presentation At J.P. Morgan Healthcare Conference

Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today...

Dec 08, 2015, 07:30 ET Envisia Therapeutics Appoints William Yelle Executive Chairman

Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today...

Nov 05, 2015, 08:20 ET Envisia Therapeutics Selected To Present During Drug Delivery Company Showcase At 2015 Ophthalmalogy Innovation Summit

Envisia Therapeutics today announced that it has been selected to present during the Drug Delivery Company Showcase at the 2015 Ophthalmology...

Oct 06, 2015, 07:00 ET Envisia Therapeutics' Lead Product Candidate, ENV515 (travoprost XR), Achieves Primary Efficacy Endpoint In Phase 2a Glaucoma Clinical Trial

Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today...